Poxel SA, a France-based company spun off from the pharmaceutical division of Merck, has raised $17.1 million in venture backing to fund a clinical trial for an experimental Type 2 diabetes drug, Bloomberg reports.
According to Bloomberg, the compound imeglimin is part of a new class of oral anti-diabetics called glimins, and has shown promising results in previous trials.
A safer alternative to existing medications could be a potentially lucrative market for ...
continue reading...